Inhibitors | Comment | Organism | Structure |
---|---|---|---|
guanosine pentaphosphate | - |
Staphylococcus aureus |
Localization | Comment | Organism | GeneOntology No. | Textmining |
---|---|---|---|---|
cytoplasm | - |
Staphylococcus aureus | 5737 | - |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Staphylococcus aureus | A0A0H2XFX6 | - |
- |
Staphylococcus aureus USA300 | A0A0H2XFX6 | - |
- |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
cyclic di-3',5'-adenylate + H2O | - |
Staphylococcus aureus | 5'-O-phosphonoadenylyl-(3'->5')-adenosine | - |
? | |
cyclic di-3',5'-adenylate + H2O | - |
Staphylococcus aureus USA300 | 5'-O-phosphonoadenylyl-(3'->5')-adenosine | - |
? | |
additional information | isoform Pde2 is capable of hydrolyzing c-di-AMP and Pde2 preferentially converts linear 5'-phosphonoadenylyl-adenosine (pApA) to AMP, reaction of EC 3.1.3.7. No substrate: ATP | Staphylococcus aureus | ? | - |
? | |
additional information | isoform Pde2 is capable of hydrolyzing c-di-AMP and Pde2 preferentially converts linear 5'-phosphonoadenylyl-adenosine (pApA) to AMP, reaction of EC 3.1.3.7. No substrate: ATP | Staphylococcus aureus USA300 | ? | - |
? |
Synonyms | Comment | Organism |
---|---|---|
PDE2 | - |
Staphylococcus aureus |
General Information | Comment | Organism |
---|---|---|
physiological function | a Pde2 mutant strain displays a growth defect in the early growth phase. Mutation leads to an increase in cellular c-di-AMP and 5'-O-phosphonoadenylyl-(3'->5')-adenosine levels and increased resistance to oxacillin | Staphylococcus aureus |